Reduced expression of p16 and p27 is correlated with tumour progression in cutaneous melanoma

References

• Lloyd R. V., Erickson L. A., Jin L., et al. p27kip1: a multifunctional cyclin‐dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 1999; 154: 313–23
   PubMed Web of Science ®Google Scholar
• Slingerland J., Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183: 10–7
   PubMed Web of Science ®Google Scholar
• Rocco J. W., Sidransky D. p16(MTS‐1/CDKN2/INK4a) in cancer progression. Exp Cell Res 2001; 264: 42–55
   PubMed Web of Science ®Google Scholar
• Ponce‐Castaneda M. V., Lee M. H., Latres E., et al. p27Kip1: chromosomal mapping to 12p12‐12p13.1 and absence of mutations in human tumors. Cancer Res 1995; 55: 1211–4
   PubMed Web of Science ®Google Scholar
• Nakayama K., Ishida N., Shirane M., et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85: 707–20
   PubMed Web of Science ®Google Scholar
• Fero M. L., Randel E., Gurley K. E., Roberts J. M., Kemp C. J. The murine gene p27Kip1 is haplo‐insufficient for tumour suppression. Nature 1998; 396: 177–80
   PubMed Web of Science ®Google Scholar
• Li Q., Murphy M., Ross J., Sheehan C., Carlson J. A. Skp2 and p27kip1 expression in melanocytic nevi and melanoma: an inverse relationship. J Cutan Pathol 2004; 31: 633–42
   PubMed Web of Science ®Google Scholar
• Morgan M. B., Cowper S. E. Expression of p‐27 (kip1) in nevi and melanomas. Am J Dermatopathol 1999; 21: 121–4
   PubMed Web of Science ®Google Scholar
• Bales E. S., Dietrich C., Bandyopadhyay D., et al. High levels of expression of p27KIP1 and cyclin E in invasive primary malignant melanomas. J Invest Dermatol 1999; 113: 1039–46
   PubMed Web of Science ®Google Scholar
• Florenes V. A., Maelandsmo G. M., Kerbel R. S., et al. Protein expression of the cell‐cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease‐free survival. Am J Pathol 1998; 153: 305–12
   PubMed Web of Science ®Google Scholar
• Orend G., Hunter T., Ruoslahti E. Cytoplasmic displacement of cyclin E‐cdk2 inhibitors p21Cip1 and p27Kip1 in anchorage‐independent cells. Oncogene 1998; 16: 2575–83
   PubMed Web of Science ®Google Scholar
• Worm J., Bartkova J., Kirkin A. F., et al. Aberrant p27Kip1 promoter methylation in malignant melanoma. Oncogene 2000; 19: 5111–5
   PubMed Web of Science ®Google Scholar
• Kamb A., Gruis N. A., Weaver‐Feldhaus J., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 436–40
   PubMed Web of Science ®Google Scholar
• Sharpless N. E. INK4a/ARF: a multifunctional tumor suppressor locus. Mutat Res 2005; 576: 22–38
   PubMed Web of Science ®Google Scholar
• Sharpless N. E., Bardeesy N., Lee K. H., et al. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 2001; 413: 86–91
   PubMed Web of Science ®Google Scholar
• Sharpless E., Chin L. The INK4a/ARF locus and melanoma. Oncogene 2003; 22: 3092–8
   PubMed Web of Science ®Google Scholar
• Thompson J. F., Scolyer R. A., Kefford R. F. Cutaneous melanoma. Lancet 2005; 365: 687–701
   PubMed Web of Science ®Google Scholar
• Tucker M. A., Goldstein A. M. Melanoma etiology: where are we?. Oncogene 2003; 22: 3042–52
   PubMed Web of Science ®Google Scholar
• Holland E. A., Schmid H., Kefford R. F., Mann G. J. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas. Genes Chromosomes Cancer 1999; 25: 339–48
   PubMed Web of Science ®Google Scholar
• Talve L., Sauroja I., Collan Y., Punnonen K., Ekfors T. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage. Int J Cancer 1997; 74: 255–9
   PubMed Web of Science ®Google Scholar
• Straume O., Sviland L., Akslen L. A. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki‐67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000; 6: 1845–53
   PubMed Web of Science ®Google Scholar
• Pavey S. J., Cummings M. C., Whiteman D. C., et al. Loss of p16 expression is associated with histological features of melanoma invasion. Melanoma Res 2002; 12: 539–47
   PubMed Web of Science ®Google Scholar
• Azzola M. F., Shaw H. M., Thompson J. F., et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. Cancer 2003; 97: 1488–98
   PubMed Web of Science ®Google Scholar
• Geradts J., Kratzke R. A., Niehans G. A., Lincoln C. E. Immunohistochemical detection of the cyclin‐dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res 1995; 55: 6006–11
   PubMed Web of Science ®Google Scholar
• Balch C. M., Buzaid A. C., Soong S. J., et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 3635–48
   PubMed Web of Science ®Google Scholar
• Sparrow L. E., Eldon M. J., English D. R., Heenan P. J. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am J Dermatopathol 1998; 20: 255–61
   PubMed Web of Science ®Google Scholar
• Straume O., Akslen L. A. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int J Cancer 1997; 74: 535–9
   PubMed Web of Science ®Google Scholar
• Alonso S. R., Ortiz P., Pollan M., et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray‐based study. Am J Pathol 2004; 164: 193–203
   PubMed Web of Science ®Google Scholar
• Gray‐Schopfer V. C., Cheong S. C., Chong H., et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16?. Br J Cancer 2006; 95: 496–505
   PubMed Web of Science ®Google Scholar
• Funk J. O., Schiller P. I., Barrett M. T., et al. p16INK4a expression is frequently decreased and associated with 9p21 loss of heterozygosity in sporadic melanoma. J Cutan Pathol 1998; 25: 291–6
   PubMed Web of Science ®Google Scholar
• Li W., Sanki A., Karim R. Z., et al. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology 2006; 38: 287–301
   PubMed Web of Science ®Google Scholar
• Sherr C. J., Roberts J. M. CDK inhibitors: positive and negative regulators of G1‐phase progression. Genes Dev 1999; 13: 1501–12
   PubMed Web of Science ®Google Scholar
• Zhang H., Schneider J., Rosdahl I. Expression of p16, p27, p53, p73 and Nup88 proteins in matched primary and metastatic melanoma cells. Int J Oncol 2002; 21: 43–8
   PubMed Web of Science ®Google Scholar
• Carlson J. A., Ross J., Murphy M. Markers of high‐risk cutaneous melanoma: is there a winning combination for individualized prognosis?. J Cutan Pathol 2005; 32: 700–3
   PubMed Web of Science ®Google Scholar
• Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high‐throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844–7
   PubMed Web of Science ®Google Scholar
• Murphy M., Carlson J. A., Keough M. P., et al. Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin‐dependent kinase inhibitor p27. J Cutan Pathol 2004; 31: 477–82
   PubMed Web of Science ®Google Scholar
• Recio J. A., Noonan F. P., Takayama H., et al. Ink4a/arf deficiency promotes ultraviolet radiation‐induced melanomagenesis. Cancer Res 2002; 62: 6724–30
   PubMed Web of Science ®Google Scholar
• Winnepenninckx V., van den Oord J. J. p16INK4A expression in malignant melanomas with or without a contiguous naevus remnant: a clue to their divergent pathogenesis?. Melanoma Res 2004; 14: 321–2
   PubMed Web of Science ®Google Scholar
• Zhang H., Rosdahl I. Ultraviolet A and B differently induce intracellular protein expression in human skin melanocytes—a speculation of separate pathways in initiation of melanoma. Carcinogenesis 2003; 24: 1929–34
   PubMed Web of Science ®Google Scholar